Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to assess the cytokine profile of tears in patients suffering from conjunctivitis versus patients without ocular involvement, when treated with Dupilumab
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Conjunctivitis | Experimental | Patients treated with Dupilumab with conjunctivitis |
|
| No conjunctivitis | Other | Patients treated with Dupilumab and showing no signs of ocular involvement |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tears sampling | Other | Tears sampling |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Increase of lacrimal inflammatory cytokines | Change in inflammatory cytokines in tears collected by capillary before and after treatment with Dupilumab. Analysis will be performed by flow cytometry. Concentrations of the following cytokines wil be measured: interleukin-1 β, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-8, interleukin-10, interleukin-13, interleukin-17, interferon α, Tumor Necrosis Factor α. | Month 8 |
| Measure | Description | Time Frame |
|---|---|---|
| Comparison of the increase of lacrimal inflammatory cytokines between the 2 groups | Change in inflammatory cytokines in tears collected by capillary among conjunctivitis patients versus non conjunctivitis patients, when treated with Dupilumab. Analysis will be performed by flow cytometry. Concentrations of the following cytokines wil be measured: interleukin-1 β, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-8, interleukin-10, interleukin-13, interleukin-17, interferon α, Tumor Necrosis Factor α. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
- pregnant or breastfeeding women
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Louise VUILLEMEY, Int | Contact | 033381669454 | louise.vuillemey@orange.fr |
| Name | Affiliation | Role |
|---|---|---|
| Camille FEBVAY, MD | CHU de Besançon | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003229 | Conjunctival Diseases |
| D003876 | Dermatitis, Atopic |
| ID | Term |
|---|---|
| D005128 | Eye Diseases |
| D012873 | Skin Diseases, Genetic |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Lashes sampling |
| Other |
Lashes sampling |
|
| Month 8 |
| Absence/Presence of demodex | Presence of demodex on lashes before treatment with Dupilumab | Day 0 |
| Increase of lacrimal eosinophiles | Month 8 |
| Improvement of quality of life | Improvement of quality of life for patients treated with Dupilumab, assessed with Ocular Surface Disease Index (OSDI) questionnaire, scored from 0 (normal/no ocular involvement) to 100 (severe ocular disease) | Month 8 |
| D003872 | Dermatitis |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D017443 | Skin Diseases, Eczematous |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |